Journal of nephrology · 2026
Temporal Patterns of HBV Reactivation in Rituximab-Treated CKD Patients: An Exploratory Analysis of Baseline Quantitative HBsAg and Prophylaxis Duration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fang Jing, Yang Yue, Wang Xu, Li Wenge, Guo Xinzhen
Аннотация
BACKGROUND: Hepatitis B virus (HBV) reactivation is a severe complication in HBsAg-positive patients receiving rituximab (RTX) for chronic kidney disease (CKD). We evaluated clinical predictors of reactivation, optimal prophylaxis duration, and post-discontinuation risk kinetics.
METHODS: We retrospectively analyzed 105 HBsAg-positive CKD patients treated with RTX. Participants were stratified by antiviral prophylaxis duration: Group A (≥ 12-18 months post-RTX, n=41), Group B (6-12 months, n=47), and Group C (< 6 months, n=17). Reactivation rates and risk factors were analyzed using univariate logistic regression, log-rank test and Kaplan-Meier survival curves.
RESULTS: The overall HBV reactivation was 7.6% (8/105). A significant "duration-dependent" protective effect was observed, with reactivation rates of 2.4%, 6.4%, and 23.5% in Groups A, B, and C, respectively (P = 0.012). Baseline HBsAg > 2.4 log10 IU/mL (OR = 12.5, P = 0.005) and antiviral prophylaxis duration < 6 months (OR = 6.8, P = 0.023) emerged as noteworthy clinical factors closely linked to reactivation risk. Furthermore, Kaplan-Meier curves confirmed a distinct temporal clustering of reactivation between 4 and 10 months following prophylaxis cessation.
CONCLUSIONS: An extended 12-18 months antiviral prophylaxis regimen provides optimal protection against HBV reactivation in CKD patients. Baseline HBsAg > 2.4 log10 IU/mL represents a noteworthy marker of heightened risk. Due to the limitations of a small event size, these findings remain exploratory and hypothesis-generating. Crucially, the observed temporal clustering between 4 and 10 months indicates a distinct post-prophylaxis risk timeline compared to non-renal populations, highlighting the need for further tailored, prospective validation.
METHODS: We retrospectively analyzed 105 HBsAg-positive CKD patients treated with RTX. Participants were stratified by antiviral prophylaxis duration: Group A (≥ 12-18 months post-RTX, n=41), Group B (6-12 months, n=47), and Group C (< 6 months, n=17). Reactivation rates and risk factors were analyzed using univariate logistic regression, log-rank test and Kaplan-Meier survival curves.
RESULTS: The overall HBV reactivation was 7.6% (8/105). A significant "duration-dependent" protective effect was observed, with reactivation rates of 2.4%, 6.4%, and 23.5% in Groups A, B, and C, respectively (P = 0.012). Baseline HBsAg > 2.4 log10 IU/mL (OR = 12.5, P = 0.005) and antiviral prophylaxis duration < 6 months (OR = 6.8, P = 0.023) emerged as noteworthy clinical factors closely linked to reactivation risk. Furthermore, Kaplan-Meier curves confirmed a distinct temporal clustering of reactivation between 4 and 10 months following prophylaxis cessation.
CONCLUSIONS: An extended 12-18 months antiviral prophylaxis regimen provides optimal protection against HBV reactivation in CKD patients. Baseline HBsAg > 2.4 log10 IU/mL represents a noteworthy marker of heightened risk. Due to the limitations of a small event size, these findings remain exploratory and hypothesis-generating. Crucially, the observed temporal clustering between 4 and 10 months indicates a distinct post-prophylaxis risk timeline compared to non-renal populations, highlighting the need for further tailored, prospective validation.